309 related articles for article (PubMed ID: 20372829)
1. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Di Marco M; Di Cicilia R; Macchini M; Nobili E; Vecchiarelli S; Brandi G; Biasco G
Oncol Rep; 2010 May; 23(5):1183-92. PubMed ID: 20372829
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs in pancreatic cancer.
Ducreux M; Boige V; Malka D
Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
[TBL] [Abstract][Full Text] [Related]
3. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
4. Cancer. Breaching the cancer fortress.
Olson P; Hanahan D
Science; 2009 Jun; 324(5933):1400-1. PubMed ID: 19520948
[No Abstract] [Full Text] [Related]
5. Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.
Cao Y; Wu L; Tan A; Liu L; Liao C; Gao F
Pancreas; 2010 Mar; 39(2):253-5. PubMed ID: 20182311
[No Abstract] [Full Text] [Related]
6. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Rocha Lima CM; Flores AM
J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
[No Abstract] [Full Text] [Related]
7. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
[TBL] [Abstract][Full Text] [Related]
8. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
9. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
[TBL] [Abstract][Full Text] [Related]
10. Conventional chemotherapy of advanced pancreatic cancer.
Giuliani F; Di Maio M; Colucci G; Perrone F
Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
[TBL] [Abstract][Full Text] [Related]
11. [Pancreatic cancer--diagnostics and therapy].
Schramm H
Zentralbl Chir; 2003 May; 128(5):367. PubMed ID: 12813632
[No Abstract] [Full Text] [Related]
12. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Conroy T; Mitry E
Bull Cancer; 2011 Dec; 98(12):1439-46. PubMed ID: 22133915
[TBL] [Abstract][Full Text] [Related]
13. [Pancreatic carcinoma: progress in therapy].
Lordick F
Krankenpfl J; 2004; 42(5-6):158-9. PubMed ID: 15527223
[No Abstract] [Full Text] [Related]
14. [Gemcitabine and pancreatic cancer].
Prost P; Ychou M; Azria D
Bull Cancer; 2002 Aug; 89 Spec No():S91-5. PubMed ID: 12449037
[TBL] [Abstract][Full Text] [Related]
15. The role of gemcitabine alone and in combination in the treatment of pancreatic cancer.
Oettle H; Arnold D; Hempel C; Riess H
Anticancer Drugs; 2000 Nov; 11(10):771-86. PubMed ID: 11142685
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine: progress in the treatment of pancreatic cancer.
Heinemann V
Oncology; 2001; 60(1):8-18. PubMed ID: 11150902
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
[TBL] [Abstract][Full Text] [Related]
18. Palliative chemotherapy for pancreatic malignancies.
Mehta SP
Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Sarvepalli D; Rashid MU; Rahman AU; Ullah W; Hussain I; Hasan B; Jehanzeb S; Khan AK; Jain AG; Khetpal N; Ahmad S
Crit Rev Oncog; 2019; 24(2):199-212. PubMed ID: 31679214
[TBL] [Abstract][Full Text] [Related]
20. [Chemoradiation for pancreatic adenocarcinoma].
Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
